Press Releases

Date Title and Summary View
Toggle Summary Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia
FREMONT, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Appoints Kenneth Greathouse to Board of Directors
FREMONT, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today
View HTML
Toggle Summary Zosano Provides Patent Application Update
FREMONT, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, received official
View HTML
Toggle Summary Zosano Presents Data from ZOTRIP Study at International Headache Society
FREMONT, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, presented data from its
View HTML
Toggle Summary Zosano Pharma Announces US Patent Office Publication of "Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines"
U S Patent Office has Published Patent Application for M207 Zolmitriptan Delivered Intracutaneously via Zosano's Proprietary Adhesive Dermally-Applied Microarray (ADAM) Technology FREMONT, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) a clinical stage
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update
John Walker appointed permanent CEO at Zosano FREMONT, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update
FREMONT, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today
View HTML
Toggle Summary Zosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicine's Pain Management Journal
FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA
Confirmation of previously announced design of Long-term Safety Study Recently completed ZOTRIP study acknowledged sufficient for NDA filing CMC development strategy confirmed adequate for registration FREMONT, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc.
View HTML
Toggle Summary Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
FREMONT, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, today announced that it has approved
View HTML